Salute_E_Benessere Chimica_E_Farmacia Chimica_E_Farmacia Salute_E_Benessere

ROCKVILLE, Md., Nov. 15, 2021 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced a partnership with MedGenome aimed at accelerating breakthrough treatments, powered by human genomics, for rare disease patients.

All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO

U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035